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Objective: To assess the clinical characteristics, prognostic factors, and treatment outcomes of primary
testicular lymphoma (PTL).
Materials and Methods: We reviewed the medical records of PTL patients diagnosed between January
2000 and May 2012 at four hospitals in Taiwan. The following data were collected and analyzed: patient
age at diagnosis, B symptoms (fever, night sweats, and/or weight loss), tumor localization (diffuse or
testis alone), tumor site (left, right, or bilateral), stage of disease, histological pattern, International
Prognostic Index, treatment method and outcome, relapse, and survival time. Kaplan Meier curves were
constructed to assess the effects of various factors on patient survival.
Results: Thirty patients with PTL were included in this study. The median age at diagnosis was 62.5 years
(range: 19 89 years) and median overall survival (OS) was 44 months. The majority of the patients had
unilateral lymphoma, stage I/II disease, and diffuse large B cell lymphoma. An absence of B symptoms,
limited disease stage, lymphoma localized to testis only, and orchidectomy were considered to be
signiﬁcantly favorable prognostic factors of OS (p < 0.05). The PTL treatment regimen varied among
patients and included orchidectomy, chemotherapy, and/or radiotherapy. Interestingly, although 50%
patients achieved complete remission (CR) post treatment, relapse was observed in 42% patients during
the follow up period. Nonetheless, patients who initially underwent orchidectomy appeared to have a
signiﬁcantly better survival rate, whereas chemotherapy proved more advantageous for those with the
diffuse type PTL.
Conclusion: PTL is characterized by unique clinical features and prognostic factors. Despite differing
treatment regimens, 50% of patients achieved CR. Patients with testicular localization who underwent
orchidectomy may achieve better outcomes, whereas chemotherapy proved to be beneﬁcial in those with
diffuse type PTL.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Primary testicular lymphoma (PTL) is a rare disease with an
estimated incidence of only 0.06e0.26 cases/100,000 persons/year
and accounts for approximately 0.6e2% of all non Hodgkin’separtment of Urology, Linkou
eishan, Taoyuan 333, Taiwan.
g).
ciation. Published by Elsevier Taiwlymphoma cases, 2e4% of all extranodal lymphoma cases, and 1e
9% of all testicular tumor cases.1 10 PTL is typically diagnosed after
orchidectomy, and the most common histological subtype is diffuse
large B cell lymphoma (DLBCL), which accounts for 70e90% of all
cases.4 6,8,9 Other reported subtypes are Burkitt’s and Burkitt’s like
lymphomas (i.e., 10e20% of cases, which are predominantly
observed in human immunodeﬁciency virus positive patients), and
rare cases of T cell, natural killer (NK)/T cell, and follicular lym
phomas of the testes.3,6,8,10 PTL is the most common type of
testicular tumor in men aged50 years.3 10 It usually presents as aan LLC. Open access under CC BY-NC-ND license.
Table 1
Patient demographics and clinical characteristics.
Variables n 30
Age (y) 61.23  15.39
Body mass index (kg/m2) 25.59  3.44
B symptoms 11 (36.7)
Weight loss 6 (20.0)
Fever 6 (20.0)
Sweating 2 (6.7)
Localization
Diffuse 18 (60.0)
Testis alone 12 (40.0)
Tumor site
Left 11 (36.7)
Right 14 (46.7)
Bilateral 5 (16.7)
Ann Arbor stage
I 12 (40.0)
II 9 (30.0)
III 1 (3.3)
IV 8 (26.7)
Histology
Diffuse large B-cell lymphoma 26 (86.7)
Diffuse large B-cell lymphoma with scattered
small T-cell lymphoma
2 (6.7)
NK/T-cell lymphoma 2 (6.7)
IPI
1 8 (53.3)
>1 7 (46.7)
Data are presented as mean  SD or n (%).
IPI International Prognostic Index; NK natural killer cell.
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bilateral involvement in some cases (8e38%).3 9 Patients also tend
to exhibit B symptoms, which include fever, weight loss, and night
sweats.5,6
Owing to its rarity, there are currently no gold standard treat
ment guidelines available for PTL.5,10 To date, the most commonly
reported treatment strategies for PTL are orchidectomy, followed
by chemotherapy and/or radiotherapy; however, its prognosis is
considered poor, with a median survival period of only 12e24
months and a 5 year overall survival (OS) rate of 16e50%.5,10 In
addition, PTL shows a predilection for spreading to extranodal sites,
primarily to the central nervous system (CNS) and contralateral
testis, and is associatedwith a high risk of relapse, evenyears after a
complete treatment response.7,8 Consequently, recent reports
recommend using a prophylactic approach that utilizes both sys
temic and intrathecal chemotherapy, as well as scrotal and
lymphatic radiotherapy, in addition to locoregional treatment.5,9,11
In an international Phase II trial, the approach adopted by Vitolo
et al,12 which incorporated a combined treatment of conventional
chemotherapy, CNS prophylaxis, and contralateral testis radio
therapy, was associated with good outcomes in patients with PTL.
Radiotherapy helped to prevent contralateral testicular relapse, but
the authors recommended further studies on CNS prophylaxis.
Clearly, a greater understanding of PTL and its response to treat
ment is needed to adequately address its poor prognosis and
associated therapeutic failure in the contralateral testis, CNS, and
extranodal sites.
Therefore, the purpose of this study was to assess the clinical
characteristics, prognostic factors of OS, and treatment outcomes of
patients with PTL to expand our current knowledge of the disease
and response to treatment.
2. Materials and methods
Using patient records from four major hospitals in Taiwan
(Linkou Chang Gung Memorial Hospital and National Taiwan Uni
versity Hospital in Taipei, China Medical University Hospital in
Taichung, and Kaohsiung Chang Gung Memorial Hospital in
southern Taiwan), we identiﬁed patients diagnosed with PTL be
tween January 2000 andMay 2012. The single inclusion criterion of
this retrospective study was a diagnosis of PTL. Patients with
testicular metastasis and patients with no recorded follow up were
excluded. In addition, one case was excluded because the patient
committed suicide. Finally, a total of 30 patients with PTL were
identiﬁed and included in this study. This study was approved by
the Institutional Ethics Committee of the aforementioned hospi
tals; however, informed patient consent was not required due to
the retrospective nature of this chart review study.
The following data were collected: patient’s age at diagnosis,
body mass index, B symptoms (deﬁned as the presence of a
recurrent fever>38 C, night sweats, andweight loss>10%within a
6 month period prior to diagnosis), tumor localization (diffuse or
testis alone), tumor site (left, right, or bilateral), stage of disease,
histological type (DLBCL, DLBCL with scattered small T cell lym
phoma, or NK/T cell lymphoma), treatment program, response rate,
relapse pattern, and survival time.
Owing to the high metastatic tendencies of PTL, all patients
underwent chest, abdominal, and pelvic computed tomography,
bone marrow biopsies, and bone scanning for PTL staging, and
were examined by an otolaryngologist for the presence of Wal
deyer’s ring. Patients were classiﬁed according to the Ann Arbor
staging system and a modiﬁed version of the International Prog
nostic Index (IPI), as previously described by Lantz et al.7 According
to the Ann Arbor staging system, stage I indicated the involvement
of a single lymph node (stage I) or a single extralymphatic organ(stage IE); stage II indicated that the cancer involved two separate
regions and that both affected areas were conﬁned to one side of
the diaphragm; stage III indicated that the cancer had spread to
both sides of the diaphragm; and stage IV indicated diffuse or
disseminated foci of involvement of one or more extralymphatic
organs or tissues, including any involvement of the liver, bone
marrow, or lung. The IPI includes ﬁve adverse prognostic factors:
age >60 years, Ann Arbor stages IIIeIV, elevated serum lactate
dehydrogenase (LDH) level, performance status 2e4, and involve
ment of more than one extranodal area. Because of the limited case
number, we classiﬁed the patients into three risk groups: low (0e1
adverse factors), intermediate, and poor risk (2 adverse factors).
Patient responses to treatment were classiﬁed into the following
three outcomes: (1) complete remission (CR), which was deﬁned as
an absence of the disease and/or relapse for a minimum of 1 month
after completion of the treatment; (2) partial remission (PR), which
was deﬁned as a decrease in tumor size by 50%; or (3) disease
progression (DP), which was deﬁned as the progression of PTL
within 1 month after treatment completion or an increase in tumor
size by <50%.
2.1. Statistical analyses
The OS rates were determined from KaplaneMeier curves and
differences between survival curves were examined using the log
rank test. Continuous data are presented as the mean  standard
deviation and categorical data by number (n) and percentage (%).
All statistical assessments were two sided and p < 0.05 was
considered statistically signiﬁcant. Statistical analyses were per
formed using SPSS statistical software (version 15.0; SPSS Inc.,
Chicago, IL, USA).
3. Results
A total of 30 patients were diagnosed with PTL between January
2000 and May 2012 in the four aforementioned hospitals. The
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years (range: 19e89 years). The follow up period of all patients was
3e128 months, with a median of 26 months. Patient demographics
and clinical characteristics are presented in Table 1. Of the 30 pa
tients, 11 (36.7%) presented with B symptoms (i.e., fever, sweats,
and/or signiﬁcant weight loss) and 12 (40.0%) presented with PTL
localized to the testis. According to the Ann Arbor staging system,
40.0% of the patients (n 12) had stage I disease, 30.0% (n 9) had
stage II, 3.3% (n 1) had stage III, and 26.7% (n 8) had stage IV
disease. Twenty six cases were characterized as DLBCL, a further
two as DLBCL with scattered small T cell lymphoma, and the
remaining two as NK/T cell lymphoma. In addition, eight patients
presentedwith low risk disease (IPI: 0e1), whereas the other seven
with intermittent or poor risk disease (IPI: 2e4). The IPI score could
not be estimated in the remaining 15 patients due to lack of LDH
data recorded.
3.1. Distribution of treatment modalities
Treatmentmodalities and outcomes of all patients are presented
in Table 2. Twenty four patients (80.0%) underwent orchidectomy
(bilateral in two patients) and six underwent biopsies. Of the 24
patients undergoing orchidectomy, four underwent orchidectomy
alone, seven underwent orchidectomy with chemotherapy, one
underwent orchidectomy with radiotherapy, seven underwent
orchidectomy with chemotherapy and radiotherapy, one under
went orchidectomy with chemotherapy and intrathecal chemo
therapy, and four underwent orchidectomy with chemotherapy,
intrathecal chemotherapy, and radiotherapy. Twelve of the twenty
four patients were classiﬁed as Ann Arbor stage I, six as stage II, and
six as stage IV. Of the six patients who underwent testis biopsy
without orchidectomy, two were administered radiotherapy alone,
one chemotherapy alone, and three received a combined treatment
of chemotherapy, intrathecal chemotherapy, and radiotherapy. Of
the group of patients who received only testicular biopsies, Ann
Arbor stages II, III, and IV consisted of three, one, and two patients,
respectively.
Regarding the total treatments delivered to all 30 patients, eight
(26.7%) received intrathecal chemotherapy (i.e., 12 mg of metho
trexate), 17 (56.7%) received radiotherapy of 3000 cGy over the
entire scrotum, and 23 (76.7%) received chemotherapy. However,
the previous chemotherapy regimens did not reach a
consensus; therefore, in recent years, the most widely used
regimen is R CHOP: rituximab (700 mg) þ cyclophosphamide
(750 mg/m2) þ doxorubicin (hydroxydaunorubicin; 50 mg/
m2) þ vincristine (Oncovin; 1 mg) þ prednisone for six cycles. We
acknowledge that the nonstandardization of the chemotherapy
regimen documented in the charts from earlier years is a limitation
of this study.Table 2
Treatments and outcomes of 30 primary testicular lymphoma
patients.
Variable n 30
Treatment
Orchidectomy 24 (80.0)
Intrathecal chemotherapy 8 (26.7)
Chemotherapy 23 (76.7)
Radiotherapy 17 (56.7)
Outcome
Complete remission 15 (50.0)
Partial response 9 (30.0)
Disease progression 6 (20.0)
Relapse 10 (42)
Data are presented as n (%).3.2. Outcomes
All patient outcomes are presented in Table 2. As shown, nine
(30%) patients achieved PR, six (20%) experienced DP, and 15 (50%)
achieved CR. Six (40%) of the 15 CR patients experienced disease
relapse with median relapse time of 40 months (range: from 10
months to 9 years). This result was in accordance with that of a
previous PTL study byMazloom et al.8 The other four of the nine PR
patients experienced disease relapse within a median time of only
9 months (range: 5e53 months). The overall relapse rate was 42%
(10 patients). The relapse sites were CNS (n 2), kidney, contra
lateral testis, liver, retrocaval lymph node, inguinal lymph node,
and bone marrow (n 1 each). The site of relapse was unknown in
two patients. Among the two patients with CNS relapse, one
received intrathecal chemotherapy.
Of the 30 patients, 16 died and 14 survived. The median survival
period for all patients was 44 months. The OS prognostic factors in
these 30 patients are presented in Table 3. As shown, an absence of
B symptoms, Ann Arbor stages IeII, tumor localization to the testis
only, and orchidectomy were all signiﬁcant and favorable prog
nostic factors of OS (p < 0.05). According to the Ann Arbor staging
system, we divided the patients as follows: limited (stages IeII) and
advanced (stages IIIeIV) stages. The median OS was 76 months
versus 12 months and the 5 year survival rate was 61% versus 17%,
respectively. We also identiﬁed a trend indicating that low IPI
might be a favorable prognostic factor (p 0.09). However, due to
the limited case number, our study results were not statistically
signiﬁcant. We found no prognostic value for patient age at diag
nosis, LDH level, bilateral or unilateral testicular involvement, tu
mor size, associated hydrocele, or involvement of the spermatic
cord or epididymis. Radiotherapy, intrathecal chemotherapy, and
systemic chemotherapy showed no beneﬁts in the treatment out
comes of patients with testicular lymphoma. However, due to the
insufﬁcient case numbers, our multivariate analysis results were
not signiﬁcant (B symptom, p 0.276; Ann Arbor stage, p 0.106;
tumor localization, p 0.178; and orchidectomy, p 0.255).
Based on lymphoma localization, patients were divided into two
groups: 12 patients with lymphoma localized to the testis only and
18 with diffuse lymphoma beyond the testis (Table 4). In the pa
tients with lymphoma localized to the testis only group, all 12
patients underwent orchidectomy. Intrathecal chemotherapy,
chemotherapy, and radiotherapy were not associated with
improvement in OS (p > 0.05). In the diffuse lymphoma group,
systemic chemotherapy was the only prognostic factor for OS
(p < 0.05). The median survival time was 40 months and 3 months
for those who underwent chemotherapy and those who did not,
respectively.
4. Discussion
Although PTL is exceptionally rare, comprising approximately
1e9% of all testicular tumors, it is the most common type of
testicular tumors in older men.1 10 In the present study, themedian
patient age was 62.5 years (range: 19e89 years), which was com
parable with the results of previous reports on PTL cases from both
Western and Asian countries, where the median age ranged from
55.0 years to 69.7 years.1 5,8,9,11,13,14 PTL commonly presents as a
unilateral painless mass in older men and ultrasonography usually
reveals diffuse or focally decreased echogenicity. Approximately
25e41% men with PTL present with B symptoms (fever, night
sweats, and weight loss)6 and approximately 26e37% cases have
elevated LDH levels.6,7,11,14 In this study, the patients were divided
using the Ann Arbor staging system as follows: limited (stages IeII)
and advanced (stages IIIeIV) stages. The median survival time was
76months versus 12 months and the 5 year OS rate was 61% versus
Table 3
Prognostic factors of overall survival rate.
Variable Patient number Median survival
(mo)
5-year overall
survival rate (%)
p
B symptom 0.011
Absent 19 65 64
Present 11 12 22
Ann Arbor stage 0.033
I II 21 76 61
III IV 9 12 17
Lymphoma localization 0.037
Testis only 12 96 61
Diffuse 18 36 41
Age 0.331
<60 12 72 59
60 18 44 41
LDH 0.902
>200 7 41 80
200 8 46 73
IPI score 0.09
Low (0 1) 8 58 75
High (2 4) 7 27 46
Tumor site 0.282
Unilateral 25 44 49
Bilateral 5 10 50
Surgery 0.049
Orchidectomy 24 76 51
Biopsy only 6 10 0
Radiotherapy 0.074
No 14 76 74
Yes 16 27 29
Systemic chemotherapy 0.27
No 7 89 58
Yes 23 51 41
Intrathecal chemotherapy 0.435
No 21 76 51
Yes 9 27 50
IPI International Prognostic Index; LDH lactate dehydrogenase.
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vious reports in which the median OS period of limited staged
disease ranged from 5.3 years to 6.3 years and the 5 year OS rate
ranged from 58% to 85%.7,8,12,14 The most favorable treatment result
was reported by Vitolo et al,12 in which all patients underwent a
treatment protocol comprising orchidectomy, R CHOP, CNS pro
phylaxis, and contralateral testis irradiation. In comparison with
the results of Vitolo et al,12 our patients received a different treat
ment protocol, andmany patients did not receive complete R CHOP
chemotherapy regimens, prophylactic radiotherapy, or intrathecal
chemotherapy. The clinical characteristics of the patients in this
study were similar to those previously reported.1,2,4,5,7,8,11,13,14 In
addition to old age, the majority of patients presented with uni
lateral stages IeII lymphoma and DLBCL. These observations sug
gest that the characteristics of PTL appear to be similar worldwide.
Although optimal PTL treatment remains uncertain due to
the rarity of the disease and lack of prospective trials, retrospective
studies recommend orchidectomy followed by systemicTable 4
Prognostic factors of lymphoma location.
Variable p
Testicular lymphoma only
Intrathecal chemotherapy 0.854
Systemic chemotherapy 0.154
Radiotherapy 0.102
Diffuse lymphoma
Orchidectomy 0.308
Intrathecal chemotherapy 0.425
Systemic chemotherapy 0.033
Radiotherapy 0.191chemotherapy and/or radiotherapy, as well as prophylactic intra
thecal chemotherapy and radiotherapy, as the ﬁrst line therapy for
against PTL.5,7,9 11 In this study, most patients underwent orchid
ectomy (80%) and chemotherapy (76.7%), and approximately half of
them underwent radiotherapy, and over a quarter received pro
phylactic intrathecal chemotherapy (26.7%). Despite the various
therapeutic regimens, half of all patients achieved CR and 30%
achieved PR. Contrary to our ﬁndings, a study by Cao et al5 on
Chinese PTL patients reported that 90% achieved CR and 3.3%
achieved PR. The better outcomes in that study may be partly
attributed to the fact that all patients underwent orchidectomy and
the majority also received chemotherapy and/or radiotherapy. In
fact, in two other studies wherein not all patients (93e95%) un
derwent orchidectomy, a lower CR rate of 67e71% was reported.8,14
Thus, undergoing orchidectomy appears to be important with re
gard to CR, although this is not surprising, as certain chemothera
peutic agents may not be effective if they are unable to cross the
bloodetestis barrier.5
Several prognostic factors have been previously reported to be
associated with improved OS, namely, good performance status,
limited disease stage, low/loweintermediate IPI, absence of B
symptoms, normal serum LDH, and beta human chorionic gonad
otropin levels, absence of a bulky mass, absence of additional
extranodal involvement, right testicular involvement, and no
relapse within 1 year post treatment.5 Our previous corroborating
observations identiﬁed the following prognostic factors of OS in the
present study: absence of B symptoms, Ann Arbor stages IeII,
lymphoma localized at the testis only, and those who underwent
orchidectomy had a signiﬁcantly better OS.
Interestingly, when patients were assessed by disease localiza
tion, it was determined that orchidectomy improved survival in
Y.-L. Tsai et al. / Urological Science 24 (2013) 89e93 93patients with PTL, whereas only systemic chemotherapy was ad-
vantageous with regard to survival in patients with diffuse
lymphoma.
Despite initially achieving CR, most patients relapse, even those
with stage IeII disease.6,11 Retrospective analyses suggest that
locoregional treatment per se largely results in relapse (i.e., in 50e
80% patients), whereas tumor recurrence in one-third of these pa-
tients is observed in the CNS or contralateral testis.5,9 In this present
study, although the majority of patients presented with stage IeII
disease (70.0%), there was a high relapse rate (overall relapse rate:
42%, stage I/II relapse rate: 35%, and stage IIIeIV relapse rate: 75%)
and a poor OS outcome (median: 44 months). Although this may be,
in part, due to lack of prophylactic therapy directed at high-risk
recurrence regions, it is uncertain whether this type of therapy
can prevent relapse and thereby warrants further investigation.
In summary, PTL patients are typically older males who experi-
ence a high rate of relapse and reportedly achieve a median OS
period of 44 months. The presence of B symptoms, diffuse locali-
zation, and advanced disease stage are associated with signiﬁcantly
decreased OS. Orchidectomy appears to improve the OS rate in PTL,
whereas chemotherapy offers more advantages for those with
advanced disease. Because orchidectomy was performed in all Ann
Arbor stage I patients, we were unable to conclude whether
orchidectomy offered any favorable prognostic effect. Nonetheless,
orchidectomy appeared to improve the complete response rate;
furthermore, the bloodetestis barriermakes the testis susceptible to
chemotherapeutic agents. Lastly, in patients with lymphoma
involvement of the testis only, we recommend that routine orchid-
ectomy be performed followed by R-CHOP chemotherapy, contra-
lateral testicular radiotherapy, and intrathecal chemotherapy.
Regarding diffuse lymphoma, although this study was unable to
demonstrate any signiﬁcant beneﬁts of orchidectomy, chemo-
therapy remains the most beneﬁcial therapy in combination with
contralateral testicular radiotherapy and intrathecal chemotherapy.
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